IUPAC/Chemical Name
1-([1,1':4',1''-Terphenyl]-2-yl)-3-(3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)urea
InChi Key
VGUQUIYJFQJLRU-UHFFFAOYSA-N
InChi Code
1S/C33H36N4O2/c1-39-32-15-8-7-14-31(32)37-24-22-36(23-25-37)21-9-20-34-33(38)35-30-13-6-5-12-29(30)28-18-16-27(17-19-28)26-10-3-2-4-11-26/h2-8,10-19H,9,20-25H2,1H3,(H2,34,35,38)
SMILES Code
O=C(NCCCN1CCN(C2=CC=CC=C2OC)CC1)NC3=CC=CC=C3C4=CC=C(C5=CC=CC=C5)C=C4
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
520.68
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Thörn CW, Kafetzopoulos V, Kocsis B. Differential Effect of Dopamine D4 Receptor Activation on Low-Frequency Oscillations in the Prefrontal Cortex and Hippocampus May Bias the Bidirectional Prefrontal-Hippocampal Coupling. Int J Mol Sci. 2022 Oct 3;23(19):11705. doi: 10.3390/ijms231911705. PMID: 36233007; PMCID: PMC9569525.
2: Kuang J, Kafetzopoulos V, Deth R, Kocsis B. Dopamine D4 Receptor Agonist Drastically Increases Delta Activity in the Thalamic Nucleus Reuniens: Potential Role in Communication between Prefrontal Cortex and Hippocampus. Int J Mol Sci. 2023 Oct 18;24(20):15289. doi: 10.3390/ijms242015289. PMID: 37894968; PMCID: PMC10607171.
3: Keck TM, Free RB, Day MM, Brown SL, Maddaluna MS, Fountain G, Cooper C, Fallon B, Holmes M, Stang CT, Burkhardt R, Bonifazi A, Ellenberger MP, Newman AH, Sibley DR, Wu C, Boateng CA. Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy. J Med Chem. 2019 Apr 11;62(7):3722-3740. doi: 10.1021/acs.jmedchem.9b00231. Epub 2019 Apr 1. PMID: 30883109; PMCID: PMC6466480.
4: Hodgson NW, Waly MI, Trivedi MS, Power-Charnitsky VA, Deth RC. Methylation- related metabolic effects of D4 dopamine receptor expression and activation. Transl Psychiatry. 2019 Nov 12;9(1):295. doi: 10.1038/s41398-019-0630-3. PMID: 31719518; PMCID: PMC6851363.
5: Śliwa P, Dziurzyńska M, Kurczab R, Kucwaj-Brysz K. The Pivotal Distinction between Antagonists' and Agonists' Binding into Dopamine D4 Receptor-MD and FMO/PIEDA Studies. Int J Mol Sci. 2024 Jan 6;25(2):746. doi: 10.3390/ijms25020746. PMID: 38255820; PMCID: PMC10815553.
